Literature DB >> 30511551

Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease.

Fareed Khdair-Ahmad1, Tariq Aladily2, Olfat Khdair-Ahmad3, Eman F Badran4.   

Abstract

Khdair-Ahmad F, Aladily T, Khdair-Ahmad O, Badran EF. Chelation therapy for secondary neonatal iron overload: Lessons learned from rhesus hemolytic disease. Turk J Pediatr 2018; 60: 335-339. Secondary neonatal iron overload occurs with intrauterine and post-natal blood transfusions. Treatment with intravenous Deferoxamine was reported only in four cases in the literature. Herein we report a case of a patient born at 36 weeks of gestation, who had rhesus hemolytic disease. He developed secondary iron overload, causing liver injury, after a total of six blood transfusions: four intrauterine and 2 post-natal transfusion therapies. Intravenous Deferoxamine treatment was started at the age of 45 days due to a ferritin level of 40,000 mg/L, progressive rise of liver enzymes, and worsening cholestasis. Treatment resulted in marked reduction in ferritin level (down to 829 mg/L at the age of 6 months), significant improvement in the liver enzymes, and resolution of cholestasis.

Entities:  

Keywords:  cholestasis; deferoxamine; intrauterine blood transfusion therapy; iron overload; neonates

Mesh:

Substances:

Year:  2018        PMID: 30511551     DOI: 10.24953/turkjped.2018.03.018

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  1 in total

1.  Early iron supplementation and iron sufficiency at one month of age in NICU patients at-risk for iron deficiency.

Authors:  Timothy M Bahr; Nicholas R Carr; Thomas R Christensen; Jacob Wilkes; Elizabeth A O'Brien; Kendell R German; Robin K Ohls; Diane M Ward; Robert D Christensen
Journal:  Blood Cells Mol Dis       Date:  2021-05-06       Impact factor: 2.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.